Prevention of Atrial Arrhythmia in Patients Without Atrioventricular (AV) Conduction Disease

NCT ID: NCT01170611

Last Updated: 2010-07-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-07-31

Study Completion Date

2007-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical investigation is a prospective, single-blinded, randomized trial. The primary objective concerns the safety and effectiveness of the AAIsafeR mode with the preventive algorithms.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, patients are randomized to DDD mode, AAIsafeR mode, or AAIsafeR mode plus atrial arrhythmia preventive algorithms. The atrial arrhythmia (AA) burden serves as the primary measure of effectiveness.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sinus Node Dysfunction Brady Tachy Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AAISAFER alone - AAISAFER+PREVENTIVE ALGORITHM - DDD

Group Type EXPERIMENTAL

PACEMAKER SYMPHONY 2550

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PACEMAKER SYMPHONY 2550

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A pacemaker indication for sinus node dysfunction and/or brady-tachy syndrome OR already implanted for less than three months for the mentioned reasons and supplied with a symphony 2550 DR at time of inclusion AND
* A PR interval \<250ms AND
* Documented atrial arrhythmia in the past year
* Medication for anti-arrhythmic must be stable for at least one month (2 months for amiodarone) prior to enrollment
* Patients must have less than two known cardioversions within the last year
* Patient has signed a consent form after having received the appropriate information

Exclusion Criteria

* Need a replacement pacemaker device
* Have an unknown PR interval
* Known AV block ≥ 250 ms PR interval
* Minor and/or pregnant woman
* Patients enrolled in other clinical trials
* Patients with sustained ventricular arrhythmia
* Patients with severe coronary artery disease (at the discretion of the investigator)
* Patients with advanced cardiomyopathy (at the discretion of the investigator)
* Patients who have sustained a myocardial infarction or undergone cardiac surgery within the past 30 days
* Patients with unstable angina pectoris
* Patients whose life expectancy is less than 1 year
* Patients who are unlikely to return for required follow-up visits
* Patients who present with permanent atrial arrhythmia or those who usually require cardioversion to terminate such arrhythmia and/or
* Patients whose physician plans to add or change medical treatment because of AA episodes during the follow-up period.
* Patient unable to understand the purpose of the study or refusing to cooperate
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

LivaNova

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Universitätklinik. Lübeck - Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Banner Baywood Heart Hospital

Mesa, Arizona, United States

Site Status

Brentwood Biomedical Research Institute

Los Angeles, California, United States

Site Status

Ochsner Clinic Foundation

New Orleans, Louisiana, United States

Site Status

University of Mississippi Medical Center

Jackson, Mississippi, United States

Site Status

Passaic Beth Israel Regional Medical Center

Passaic, New Jersey, United States

Site Status

NorthEast Medical Center

Concord, North Carolina, United States

Site Status

Hillcrest Medical Center

Tulsa, Oklahoma, United States

Site Status

Lancaster Regional Medical Center

Lancaster, Pennsylvania, United States

Site Status

Drexel University College of Medicine

Philadelphia, Pennsylvania, United States

Site Status

OLV Aalst

Aalst, , Belgium

Site Status

Cliniques Sud Luxembourg

Arlon, , Belgium

Site Status

Clinique Saint-Jean

Brussels, , Belgium

Site Status

Algemeen Ziekenhuis Sint-Dimpna

Geel, , Belgium

Site Status

Centre Hospitalier Hutois

Huy, , Belgium

Site Status

CHU Tivoli

La Louvière, , Belgium

Site Status

Algemeen Ziekenhuis Sint-Augustinus

Wilrijk, , Belgium

Site Status

UCL Mont-Godinne

Yvoir, , Belgium

Site Status

CHG d'Albi

Albi, , France

Site Status

CHRU du Morvan Hôpital la Cavale Blanche

Brest, , France

Site Status

Hospice St-Jacques-Hôpital G.Montpied

Clermond-Ferrand, , France

Site Status

Hôpital Henri Mondor

Créteil, , France

Site Status

C.H.I. du Val d'Ariège

Foix, , France

Site Status

CHRU de Grenoble Hôpital Michallon

Grenoble, , France

Site Status

Polyclinique du Bois

Lille, , France

Site Status

CHU de Limoges Hôpital Dupuytren

Limoges, , France

Site Status

Clinique Clairval

Marseille, , France

Site Status

Hôpital Arnaud de Villeneuve

Montpellier, , France

Site Status

Polyclinique de Gentilly

Nancy, , France

Site Status

Nouvelles Cliniques Nantaises

Nantes, , France

Site Status

Hôpital Pasteur

Nice, , France

Site Status

Hôpital Pitié-Salpêtrière

Paris, , France

Site Status

InParys CLINIQUE BIZET

Paris, , France

Site Status

CHU Haut l'Evêque

Pessac, , France

Site Status

CHU Pontchaillou

Rennes, , France

Site Status

CHU - Hôpital Charles Nicolle

Rouen, , France

Site Status

Centre Cardiologique du Nord

Saint-Denis, , France

Site Status

Centre Hospitalier Rangueil

Toulouse, , France

Site Status

CHU Brabois

Vandœuvre-lès-Nancy, , France

Site Status

Hufeland Krankenhaus GmbH

Bad Langensalza, , Germany

Site Status

Charite Campus Virchow

Berlin, , Germany

Site Status

Kliniken der Stadt Köln

Cologne, , Germany

Site Status

Universitätklinikum Leipzig

Leipzig, , Germany

Site Status

Universitätklinik. Lübeck

Lübeck, , Germany

Site Status

Klinikum Lüdenscheid

Lüdenscheid, , Germany

Site Status

Johannes Gutenberg-Universität - Mainz Klinikum

Mainz, , Germany

Site Status

Klinikum Memmingen

Memmingen, , Germany

Site Status

Ospedale San Tommaso dei Battuti

Portogruaro, VE, Italy

Site Status

CH Princesse Grace

Monaco, , Monaco

Site Status

Complejo Hospitalario Universitario de Vigo (CHUVI)

Pontevedra, , Spain

Site Status

Eastbourne District General Hospital

Eastbourne, East Sussex, United Kingdom

Site Status

St Peters Hospital

Chertsey, Surrey, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium France Germany Italy Monaco Spain United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IPRE03

Identifier Type: -

Identifier Source: secondary_id

PREFACE-IPRE03

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

LEAF - Low Energy In Atrial Fibrillation
NCT00157781 COMPLETED PHASE4
CLOSE to CURE Study
NCT02925624 COMPLETED NA